AstraZeneca Updates on AL Amyloidosis Drug Anselamimab
Ticker: AZN · Form: 6-K · Filed: Jul 16, 2025 · CIK: 901832
| Field | Detail |
|---|---|
| Company | Astrazeneca PLC (AZN) |
| Form Type | 6-K |
| Filed Date | Jul 16, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: drug-update, clinical-trial, rare-disease
TL;DR
AZN provides an update on anselamimab for AL amyloidosis.
AI Summary
AstraZeneca PLC announced an update on its investigational drug anselamimab for AL amyloidosis on July 16, 2025. The company is providing this information as part of its ongoing reporting requirements.
Why It Matters
This update provides stakeholders with the latest information on the development of anselamimab, a potential new treatment for AL amyloidosis, a rare and serious disease.
Risk Assessment
Risk Level: low — This filing is a routine report of foreign issuer information and does not contain new material financial or strategic information.
Key Players & Entities
- AstraZeneca PLC (company) — Registrant
- anselamimab (drug) — Investigational drug for AL amyloidosis
- AL amyloidosis (disease) — Condition being treated
- July 2025 (date) — Reporting period
- 001-11960 (filing_id) — SEC File Number
FAQ
What is the purpose of this Form 6-K filing?
The purpose of this Form 6-K filing is to report information as a foreign issuer for the month of July 2025, specifically providing an update on the investigational drug anselamimab in AL amyloidosis.
What is the company's SEC file number?
The company's SEC file number is 001-11960.
What is the primary subject of the update mentioned in the filing?
The primary subject of the update is anselamimab, an investigational drug for the treatment of AL amyloidosis.
Does AstraZeneca file its annual reports under Form 20-F or Form 40-F?
AstraZeneca PLC indicates that it files its annual reports under cover of Form 20-F.
Where is AstraZeneca PLC's principal executive office located?
AstraZeneca PLC's principal executive office is located at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on July 16, 2025 regarding ASTRAZENECA PLC (AZN).